Maternal depression, antidepressantuse in pregnancy and Apgar scores in infants

British Journal of Psychiatry

Volumn 202, Issue 5, 2013, Pages 347-351

  Jensen, Hans Mørch ^a   Grøn, Randi ^b   Lidegaard, Øjvind ^c   Pedersen, Lars Henning ^d   Andersen, Per Kragh ^a   Kessing, Lars Vedel ^c  

^a Mental Health Services CPH   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Rigshospitalet   (Denmark)

^d AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; LITHIUM; SEROTONIN UPTAKE INHIBITOR;

ADULT; APGAR SCORE; ARTICLE; DENMARK; DRUG USE; FEMALE; GESTATIONAL AGE; HUMAN; INFANT; MAJOR CLINICAL STUDY; PREGNANT WOMAN; PRENATAL EXPOSURE; PRESCRIPTION; PUERPERAL DEPRESSION; MAJOR DEPRESSION; PREGNANCY; PREGNANCY COMPLICATION; REGRESSION ANALYSIS; RISK FACTOR;

ADULT; ANTIDEPRESSIVE AGENTS; APGAR SCORE; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTERS; PRENATAL EXPOSURE DELAYED EFFECTS; REGRESSION ANALYSIS; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS;

EID: 84877629647     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.112.115931     Document Type: Article

References (39)

1. Cooper WO, Willy ME, Pont SJ, Ray WA. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 2007; 196: 544-5.
2. Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, Boudreau D, et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 2008; 198: 194-5.
3. Alwan S, Reefhuis J, Rasmussen SA, Friedman JM. Patterns of antidepressant medication use among pregnant women in a United States population. J Clin Pharmacol 2011; 51: 264-70.
4. Kinney HC, Belliveau RA, Trachtenberg FL, Rava LA, Paterson DS. The development of the medullary serotonergic system in early human life. Auton Neurosci 2007; 132: 81-102. (Pubitemid 46274542)
5. Wadhwa PD, Glynn L, Hobel CJ, Garite TJ, Porto M, Chicz-DeMet A, et al. Behavioral perinatology: biobehavioral processes in human fetal development. Regul Pept 2002; 108: 149-57. (Pubitemid 35239872)
6. O'Keane V, Marsh MS. Depression during pregnancy. BMJ 2007; 334: 1003-5. (Pubitemid 46808368)
7. Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005; 293: 2372-83. (Pubitemid 40676760)
8. Lorenzo L, Byers B, Einarson A. Antidepressant use in pregnancy. Expert Opin Drug Saf 2011; 10: 883-9.
9. Koren G, Nordeng H. Antidepressant use during pregnancy: the benefit-risk ratio. Am J Obstet Gynecol 2012; 207: 157-63.
10. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006; 63: 898-906. (Pubitemid 44188483)
11. Odd DE, Rasmussen F, Gunnell D, Lewis G, Whitelaw A. A cohort study of low Apgar scores and cognitive outcomes. Arch Dis Child Fetal Neonatal Ed 2008; 93: F115-20. (Pubitemid 352038500)
12. Stuart A, Otterblad OP, Kallen K. Apgar scores at 5 minutes after birth in relation to school performance at 16 years of age. Obstet Gynecol 2011; 118: 201-8.
13. Odd DE, Gunnell D, Lewis G, Rasmussen F. Long-term impact of poor birth condition on social and economic outcomes in early adulthood. Pediatrics 2011; 127: e1498-504.
14. Ehrenstein V, Pedersen L, Grijota M, Nielsen GL, Rothman KJ, Sorensen HT. Association of Apgar score at five minutes with long-term neurologic disability and cognitive function in a prevalence study of Danish conscripts. BMC Pregnancy Childbirth 2009; 9: 14.
15. Ehrenstein V. Association of Apgar scores with death and neurologic disability. Clin Epidemiol 2009; 1 : 45-53.
16. Knudsen LB, Olsen J. The Danish Medical Birth Registry. Dan Med Bull 1998; 45: 320-3. (Pubitemid 28313542)
17. Danish National Board of Health (Lægemiddelstyrelsen). Medicinal Product Statistics. Danish Health and Medicines Authority, 2011 (www.laegemiddelstyrelsen.dk).
18. Munk-Jørgensen P, Kastrup M, Mortensen PB. The Danish Psychiatric Register as a tool in epidemiology. Acta Psychiatr Scand 1993; 87: 27-32. (Pubitemid 23063720)
19. World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD-8). WHO, 1967.
20. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. WHO, 1992.
21. Statistics Denmark. Employment. Statistics Denmark, 2011 (www.dst.dk).
22. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004; 158: 312-6. (Pubitemid 38451555)
23. Lund N, Pedersen LH, Henriksen TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med 2009; 163: 949-54.
24. Oberlander TF, Bonaguro RJ, Misri S, Papsdorf M, Ross CJ, Simpson EM. Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol Psychiatry 2008; 13: 65-73. (Pubitemid 350275180)
25. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002; 159: 2055-61. (Pubitemid 35423865)
26. Wisner KL, Sit DK, Hanusa BH, Moses-Kolko EL, Bogen DL, Hunker DF, et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009; 166: 557-66.
27. Lewis AJ, Galbally M, Opie G, Buist A. Neonatal growth outcomes at birth and one month postpartum following in utero exposure to antidepressant medication. Aust NZ J Psychiatry 2010; 44: 482-7.
28. Udechuku A, Nguyen T, Hill R, Szego K. Antidepressants in pregnancy: a systematic review. Aust NZ J Psychiatry 2010; 44: 978-96.
29. Casper RC, Gilles AA, Fleisher BE, Baran J, Enns G, Lazzeroni LC. Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development. Psychopharmacology (Berl) 2011; 217: 211-9.
30. Lu J, Sherman D, Devor M, Saper CB. A putative flip-flop switch for control of REM sleep. Nature 2006; 441: 589-94. (Pubitemid 43927285)
31. Bairy KL, Madhyastha S, Ashok KP, Bairy I, Malini S. Developmental and behavioral consequences of prenatal fluoxetine. Pharmacology 2007; 79: 1-11. (Pubitemid 46034171)
32. Branchereau P, Chapron J, Meyrand P. Descending 5-hydroxytryptamine raphe inputs repress the expression of serotonergic neurons and slow the maturation of inhibitory systems in mouse embryonic spinal cord. J Neurosci 2002; 22: 2598-606. (Pubitemid 37465809)
33. Maciag D, Simpson KL, Coppinger D, Lu Y, Wang Y, Lin RC, et al. Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology 2006; 31: 47-57. (Pubitemid 43250940)
34. Noorlander CW, Ververs FF, Nikkels PG, van Echteld CJ, Visser GH, Smidt MP. Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities. PLoS One 2008; 3: e2782.
35. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004; 158: 312-6. (Pubitemid 38451555)
36. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002; 159: 2055-61. (Pubitemid 35423865)
37. Ericson A, Kallen B, Wiholm BE. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999; 55: 503-8. (Pubitemid 29446550)
38. Wen SW, Yang QY, Garner P, Fraser W, Olatunbosun O, Nimrod C, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006; 194: 961-6.
39. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004; 158: 312-6. (Pubitemid 38451555)